Murakami, Yasutaka
Todo, Kenichi http://orcid.org/0000-0001-7711-3466
Uchida, Kazutaka
Yamagami, Hiroshi
Sakai, Nobuyuki
Gon, Yasufumi
Okazaki, Shuhei
Sasaki, Tsutomu
Yoshimura, Shinichi
Morimoto, Takeshi
Mochizuki, Hideki
Funding for this research was provided by:
Osaka University
Article History
Accepted: 25 January 2024
First Online: 31 March 2024
Declarations
:
: K. Todo reports lecture fees from Pfizer, Bristol-Myers Squibb, Daiichi-Sankyo, Bayer. K. Uchida reports lecturer’s fees from Daiichi Sankyo. H. Yamagami discloses research grants from Bristol-Myers Squibb; lecturer’s fees from Bayer, Daiichi Sankyo, Bristol-Myers Squibb, Otuska Pharmaceutical, Stryker and Medtronic; and membership of the advisory boards for Daiichi Sankyo. N. Sakai reports lecturer’s fees from Daiichi Sankyo. S. Yoshimura discloses research grants from Bristol-Myers Squibb and lecturer’s fees from Boehringer Ingelheim, Daiichi Sankyo, Bayer, Pfizer, and Bristol-Myers Squibb. T. Morimoto reports lecturer’s fees from Daiichi Sankyo and Pfizer, a manuscript fee from Pfizer, and membership of the advisory boards for Bristol-Myers Squibb. No other disclosures were reported.
: This study was conducted in accordance with the Declaration of Helsinki, and all methods were carried out per the relevant guidelines and regulations for observational studies. The institutional review boards of all 38 participating centers approved the study protocol. This procedure was approved by the institutional review boards in accordance with the Ethical Guidelines for Medical and Health Research Involving Human Subjects in Japan.
: A written informed consent was obtained from the prospectively registered patients and from the opt-out method from the retrospectively registered patients.